DX / Differentials / MULTI-SPECIALTY MSO

D-05 — PREPARING FOR SALE · MULTI-SPECIALTY MSO

Growth has to read as a system — MSOs

Growth has to read as referral capture, not as acquisitions

DIFFERENTIAL — LIKELY CAUSES, MOST LIKELY FIRST

1. 01

   Growth is inorganic and the same-store line will not carry the story

   A buyer prices repeatability. Revenue added by acquisition is priced as the acquisition; revenue added by same-clinic performance is priced as a system. The two are separated in diligence whether or not they were separated in management reporting.

   Physician groups have declined as a share of all global provider transactions, from 28% in 2021 to 23% in 2025, even as global healthcare private equity set a record with approximately $190 billion in deal value across 445 announced buyouts. Bain's own stated conclusion is that physician-group investment has evolved past the simple buy-and-build roll-up model and now demands greater operational sophistication.

   Bain & Company, Global Healthcare Private Equity Report 2026. Note Bain's own surfaces report $190B and $191B; use "approximately $190 billion." Bain excludes add-ons below $250M, so it measures the top of the market, not the tuck-in middle.

   NOT THIS IF — Not this if same-clinic revenue per FTE physician has grown independently of acquisitions for eight consecutive quarters on a consistent definition.

2. 02

   Referral capture is undocumented, so a real revenue line is unauditable

   If the group cannot establish whether a referred patient was seen, neither can a quality-of-earnings team. Unauditable revenue does not get a multiple; it gets a question, and questions in diligence get priced.

   In the only peer-reviewed referral series with a stated denominator, 40,377 of 103,737 referral scheduling attempts (38.9%) had no documented status at all, and only 34.8% resulted in documented completed appointments — inside a single integrated health system where capture should be easiest.

   Patel MP et al., J Gen Intern Med. 2018;33(5):715-721. One academic health system, July 2015 – June 2016.

   NOT THIS IF — Not this if a closed referral cohort resolves to terminal states and the completion series is reportable by quarter. That series is itself a diligence asset.

3. 03

   The cost trajectory reads as structural rather than addressed

   A buyer extrapolates the trend line. A group whose cost per physician has compounded faster than its revenue per physician for five years is priced on that curve unless the inflection is documented.

   Median total operating cost per FTE physician rose from $620,098 to $801,938 (+29.3%) over five years while total medical revenue per FTE physician rose 16.6%. Over 2011–2024, CPI rose 39.5% while operating cost per FTE physician rose 71.6% at physician-owned multispecialty groups and 83.3% at hospital-/IDS-owned groups. At system-affiliated groups, median loss per physician exceeds $249,000. Median investment per provider FTE did improve, from $175,517 (2023) to $161,592 (2024) — proof the curve can bend.

   MGMA DataDive Cost and Revenue; MGMA Stat, "Does your margin have breathing room?"; AMGA 2023 (5,700+ clinics) and AMGA 2024 (7,500+ clinics, 31,000+ providers) Medical Group Operations and Finance Surveys.

   NOT THIS IF — Not this if the group can show four or more consecutive quarters where revenue per FTE physician grew faster than operating cost per FTE physician, on one definition.

4. 04

   Compensation-to-production has no defensible fair-market-value citation behind it

   Stark and Anti-Kickback make provider compensation-to-production a compliance artefact, not a management preference. A comp model that cannot cite a named survey, edition, and percentile is a diligence exposure regardless of how reasonable it is.

   The two citations valuation firms actually use: MGMA DataDive Provider Compensation, 2025 report, covering more than 220,000 physicians and APPs — median surgical specialist total compensation of nearly $585,000 in 2024, up 5.57%; and SullivanCotter's 2025 Physician Compensation and Productivity Survey, 500+ organisations, approximately 231,300 physicians, 232 specialties, reporting adult medical specialties up 7.5% from 2024 to 2025 and primary care up 21.8% over five years.

   MGMA DataDive Provider Compensation, 2025 report; SullivanCotter 2025 Physician Compensation and Productivity Survey.

   NOT THIS IF — Not this if every comp arrangement already carries a named survey, edition, specialty, and percentile in its file. Where a valuation firm holds those subscriptions, they are the right party — this is not a marketing deliverable.

5. 05

   Fabricated benchmarks are sitting inside the group's own materials

   A diligence team that checks one circulating benchmark and finds it hollow re-checks every other number in the book. The cost is not the benchmark; it is the credibility of everything adjacent to it.

   Three that are widely quoted around medical groups and should never appear in a management presentation. The 2,500-patient primary care panel has no empirical basis — it traces to a 2000 article by Murray and Tantau who speculated about an upper range without data; Raffoul et al. calculate that a family physician would need 21.7 hours per work day to deliver recommended care to 2,500, and observed panels run 1,200–1,900 (Kaiser Permanente 1,751, Veterans Affairs 1,266 per FTE). "$2.4 million generated per physician" comes from Merritt Hawkins' 2019 revenue survey: 62 completed surveys covering 93 separate hospitals, which Merritt Hawkins itself calls a relatively small data set, in a year whose $2,378,727 result was a 52% single-cycle jump from the approximately $1.4–1.5 million reported in every prior wave. And the claim that ancillary integration produces "15–25% higher net revenue," attributed to MGMA by healthwrighttechnologies.com, has no MGMA document behind it at all.

   Raffoul M, Moore M, Kamerow D, Bazemore A. "A Primary Care Panel Size of 2500 Is Neither Accurate nor Reasonable." J Am Board Fam Med. 2016;29(4):496-499; Merritt Hawkins (AMN Healthcare) 2019 Physician Inpatient/Outpatient Revenue Survey, methodology section read at source; healthwrighttechnologies.com attribution — no corresponding MGMA document located.

   NOT THIS IF — Never excluded without checking. Search the CIM, the management deck, and the website for these three before anyone outside the group does.

HOW TO TELL THEM APART

How to tell these apart in your own numbers

Each of these is a measurement you can run yourself, without us.

WHAT RESOLVES EACH

What resolves this, and how you will know it resolved

Growth is inorganic and the same-store line will not carry the story	Rx 05 · preparing for sale →	Same-clinic performance separated from platform performance, presented as a series rather than an assertion. What does not work: a growth narrative that blends the two. Diligence separates them anyway, and the separation lands worse when the buyer does it.
Referral capture is undocumented, so a real revenue line is unauditable	Rx 03 · patient conversion →	Close the loop operationally first — a capture series cannot be reported until referral orders and completed encounters reconcile. Twelve to eighteen months is enough time to build four reportable quarters, which is the minimum a buyer will treat as a trend.
The cost trajectory reads as structural rather than addressed	Rx 04 · marketing attribution →	Tied to the income statement, one definition, quarterly. The bend in the curve is the asset; an undocumented bend is worth nothing in a data room.
Compensation-to-production has no defensible fair-market-value citation behind it	Rx 05 · preparing for sale →	Documentation, not design. This is compliance territory and a valuation firm holding the MGMA and SullivanCotter subscriptions is the right owner — we would point there rather than substitute for it.
Fabricated benchmarks are sitting inside the group's own materials	Rx 05 · preparing for sale →	A source audit of every external figure in the exit materials. It is the cheapest item on this list and the one with the worst downside if skipped, because a single hollow benchmark converts a diligence review into a re-verification of everything.

HOW THIS DIFFERS BY SCALE

How this differs by scale

Single site	One site rarely runs a process alone — it is usually the tuck-in. What matters here is being the acquisition that produces clean numbers: one definition, a reconcilable referral loop, and a comp arrangement that traces to a named survey edition. That is the whole list.
Group	Three to fifteen sites is where same-store separation first becomes possible and first becomes necessary. Note the buyer's own stated reasons for selling from the AMA's national survey: better payer rate negotiation (70.8%), access to costly resources (64.9%), managing payer regulatory and administrative requirements (63.6%), and easing participation in risk-based payment (55.1%). The story that lands is the one addressing those, not a marketing story.
Platform	Fifty-plus providers, mixed ownership, multiple EHR instances. Same-store must be defined against a fixed cohort or it can be manufactured by cohort selection — and a buyer will test exactly that. Bain's read is that the buy-and-build era has given way to a demand for operational sophistication, so the platform-level artefact worth building is proof that the operating model transfers to an acquired site, measured on the acquired site.

OTHER PRESENTATIONS — MULTI-SPECIALTY MSO

• wRVUs per FTE physician are up. Total medical revenue per FTE physician is not.
• Cost per encounter is rising — and the marketing line is the one number nobody publishes
• Referrals are being placed. Nobody can say whether the patient was seen.
• Same staffing ratio. Sevenfold different economics.